Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.62 |
| ▸ | TP53 | P04637 | 6/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | RNF4 | P78317 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29542273 | 0.90 | SMN1; SMN2 (0.56) | SMN1; SMN2TP53GAARNF4MAPT | |
| SCHEMBL22178978 | 0.90 | SMN1; SMN2 (0.56) | SMN1; SMN2TP53GAARNF4MAPT | |
| SCHEMBL22165369 | 0.81 | SMN1; SMN2 (0.49) | SMN1; SMN2TP53MAPTKDM4EMEN1 | |
| SCHEMBL29541701 | 0.81 | SMN1; SMN2 (0.49) | SMN1; SMN2TP53MAPTKDM4EMEN1 | |
| SCHEMBL22165818 | 0.81 | SMN1; SMN2 (0.49) | SMN1; SMN2TP53MAPTKDM4EMEN1 | |
| SCHEMBL4687567 | 0.75 | LMNA (0.56) | SMN1; SMN2TP53GAARNF4MAPT | |
| SCHEMBL22165348 | 0.73 | SMN1; SMN2 (0.46) | SMN1; SMN2TP53MAPTKDM4EALDH1A1 | |
| SCHEMBL22165490 | 0.73 | LIPE (0.48) | SMN1; SMN2TP53MAPTMEN1KMT2A | |
| SCHEMBL22179002 | 0.72 | MEN1 (0.41) | SMN1; SMN2TP53MAPTKDM4EALDH1A1 | |
| SCHEMBL22165446 | 0.71 | HTT (0.46) | SMN1; SMN2GAAMAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3902804-A1 | AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | Les Laboratoires Servier SAS (FR) | 2021-11-03 | — | — | EP | disclosed |
| WO-2020139992-A1 | AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | AGIOS PHARMACEUTICALS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |